Prof Mhairi Copland speaks with ecancertv at ASH 2016 from the DESTINY study, a UK assessment of safely reducing dosage of tyrosine kinase therapy for patients with a deep molecular response.

She describes the rationale behind the destiny study, based on TKIs most commonly prescribed to treat CML, and considers the patient benefits associated with dose reduction, including better outlooks on adverse events and affordability.

Coverage of the press conference in which these results were first presented is available here, and more detail is available through ecancer news here.

Cessation of TKI therapy was also discussed at ASH 2016 by Dr Francois-Xavier Mahon, here, and these results were reviewed together by Dr Mikkael Sekeres here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.